In the phase III POLARGO trial, @drmatasar.bsky.social reported that adding polatuzumab vedotin to R-GemOx reduced mortality by ~40% in relapsed/refractory DLBCL.
📊 270 patients
⏱️ Median OS: 19.5 vs 12.5 months (HR 0.60)
🔗 ascopost.com/issues/july-...
#DLBCL #PolatuzumabVedotin